On 20 June 2018 members of the House of Lords debated the issues surrounding the huge increase in the cost of liothyronine. The impact on some patients affected by this has been enormous and has caused great distress.
Some excellent points were made during the debate and all parties appeared to feel that progress had been made. In particular Lord O'Shaughnessy, the Parliamentary Under-Secretary of State for the Department of Health, made a commitment to pursuing with NHS England further ways in which they can clarify to CCGs the guidelines that set out the circumstances under which liothyronine should be prescribed.
We are grateful to the members of the House of Lords and all the patients who contributed to this important debate. A full transcript of the debate can be found by following this link.